BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines tEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL) & MD&A
Latest, Q2 2026
229
Period ended Jun 30, 2026
Change on a year earlier
+18.1%
194 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 229 | +18.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 206 | +20.4% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 182 | +18.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 191 | +16.7% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 194 | +22.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 171 | +17.8% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 154 | +20.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 163 | +13.2% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 158 | +6.0% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 145 | +26.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 128 | +25.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 144 | +12.6% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 150 | +42.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 115 | +31.1% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 102 | +87.9% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 128 | +66.5% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 105 | +40.1% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 87.6 | +79.1% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 54.4 | -14.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 77 | +54.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 74.9 | +154.8% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 48.9 | +138.5% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 63.5 | – | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 49.9 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 29.4 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 20.5 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 0 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 0 | – | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 0 | – | Form 10-Q (filed 2020-05-11) ↗ |
Breakdown
What makes up tevimbra (tislelizumab, anti-pd-1) — global net product revenue ($m)
Cite this data
StockData. (2026). BeOne Medicines TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_tevimbra_ww
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.